Search | Engineering

Subscribe Submit

Home Journals Focus Achievement Fronts About Us 中文版

Resource Type

Journal Article 3

Year

2022 1

2018 1

2009 1

Keywords

Enterobacter cloacae 1

AmpC β-lactamase 1

Carbapenem-resistant 1

Ceftazidime–avibactam 1

Enterobacteriaceae 1

Resistance mechanism 1

carbapenem 1

drug resistance 1

phylogenetic analysis 1

β-lactam/β-lactamase inhibitor 1

β-lactamase genes 1

open ︾

Search scope:

排序： Display mode:

Detection of AmpC β-lactamase and drug resistance of

Rong WANG, Shangwei WU, Xue LI, Ping HE, Yunde LIU

Frontiers of Medicine 2009, Volume 3, Issue 1, Pages 72-75 doi: 10.1007/s11684-009-0004-y

Abstract: The AmpC enzyme was detected by the five-disk diffusion test.Antibiotic sensitivity test showed thatMeanwhile, the phenotype detection showed that 35.06% (27/77) isolates of produced AmpC β-lactamase.Sulperazone (cefoperazone/sulbactam), a kind of component β-lactamase, is a more effective antibioticof the third generation cephalosporins plays an important role in leading to emergence of high-yield AmpCβ-lactamase strains, so antibiotics should be used wisely.

Keywords： Enterobacter cloacae AmpC β-lactamase drug resistance

HTML PDF Collect

Prevalence and drug resistance characteristics of carbapenem-resistant Enterobacteriaceae in Hangzhou, China

Yan Yang, Jian Chen, Di Lin, Xujian Xu, Jun Cheng, Changgui Sun

Frontiers of Medicine 2018, Volume 12, Issue 2, Pages 182-188 doi: 10.1007/s11684-017-0529-4

Abstract: Resistant β-lactamase genes were identified by polymerase chain reaction and sequencing.A total of 123 strains harbored more than two kinds of β-lactamase genes. , , , and were the predominant

Keywords： Enterobacteriaceae carbapenem β-lactamase genes phylogenetic analysis

HTML PDF Collect

Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria Review

Tingting Xu, Yuqi Guo, Yang Ji, Baohong Wang, Kai Zhou

Engineering 2022, Volume 11, Issue 4, Pages 138-145 doi: 10.1016/j.eng.2020.11.004

Abstract: Ceftazidime–avibactam (CAZ–AVI) is a novel cephalosporin/β-lactamase inhibitor combinationrecently identified resistance mechanisms of CAZ–AVI, with a focus on the production of β-lactamase

Keywords： Ceftazidime–avibactam Resistance mechanism Carbapenem-resistant β-lactam/β-lactamase inhibitor